Cancer clinical trials in the region Île-de-France
684 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT05280509
Phase 2 Cohorte 2 (réponse sous-optimale au ruxolitinib)
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis
Secondary myelofibrosis
Required number of previous lines of therapy
1
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1
Intermediate-2
High
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Telios Pharma, Inc.
Phase 1 / Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT05280509
Phase 2 Cohorte 1 Myélofibrose naïve au traitement par JAKi
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis
Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required DIPSS scores
Intermediate-1
Intermediate-2
High
Excluded previous treatments
Targeted therapy
5 recruiting sites
Telios Pharma, Inc.
Phase 1 / Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT05601726
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Secondary MDS
Required number of previous lines of therapy
1
2
3 or more
Required IPSS-R prognostic scores
High
Very high
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Advanced BioDesign
Phase 1 / Phase 2
Acute leukemia
#NCT05601726
Required histologic types
Acute myeloid leukemia (AML)
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Advanced BioDesign
Phase 1 / Phase 2
Acute leukemia
#NCT04771130
#2021-003285-12
Parties 1, 2 et 3 cohortes LAM
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
Excluded previous treatments
Targeted therapy
3 recruiting sites
BeOne Medecines
Phase 1 / Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT04176198
#2022-502597-16-00
Bras Nuvisertib (TP-3654) + Ruxolitinib
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis
Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1
Intermediate-2
High
Required M-IPSS70+ v2.0 scores
Intermediate
High
Required MYSEC-PM scores
Intermediate-1
Intermediate-2
High
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT04176198
#2022-502597-16-00
Bras Nuvisertib (TP-3654) + Momelotinib
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis
Secondary myelofibrosis
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1
Intermediate-2
High
Required M-IPSS70+ v2.0 scores
Intermediate
High
Required MYSEC-PM scores
Intermediate-1
Intermediate-2
High
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT04176198
#2022-502597-16-00
Bras de monothérapie par nuvisertib
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis
Secondary myelofibrosis
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1
Intermediate-2
High
Required M-IPSS70+ v2.0 scores
Intermediate
High
Required MYSEC-PM scores
Intermediate-1
Intermediate-2
High
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2
Prostate cancer
#NCT07190300
#2025-521873-15-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Internal Vectorised Radiotherapy (IVR)
3 recruiting sites
Novartis
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06898450
Parties A and B (Patients non sélectionnés)
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Nimbus Wadjet, Inc.